Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioAge Labs, Inc. - Common Stock (NQ:BIOA)

6.010 +0.710 (+13.40%)
Streaming Delayed Price Updated: 1:14 PM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 878,059
Open 5.690
Bid (Size) 5.990 (2)
Ask (Size) 6.010 (1)
Prev. Close 5.300
Today's Range 5.650 - 6.110
52wk Range 2.880 - 26.62
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This Badger Meter Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
 
Via Benzinga
BIOAGE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
+8.1%
+8.1%
1 Month
+17.6%
+17.6%
3 Month
+26.3%
+26.3%
6 Month
+43.1%
+43.1%
1 Year
-76.7%
-76.7%

More News

Read More
BioAge Labs to Present at Upcoming Investor Conferences
From BioAge Labs, Inc.
Via GlobeNewswire
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
From BioAge Labs, Inc.
Via GlobeNewswire
BioAge Labs (BIOA) Q2 Revenue Hits $2.4M
Via The Motley Fool
Topics Intellectual Property
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates
From BioAge Labs, Inc.
Via GlobeNewswire
BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
From BioAge Labs, Inc.
Via GlobeNewswire
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank
From BioAge Labs, Inc.
Via GlobeNewswire
BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates
From BioAge Labs, Inc.
Via GlobeNewswire
BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic
From BioAge Labs, Inc.
Via GlobeNewswire
BioAge Labs to Present at Upcoming Investor Conferences
From BioAge Labs, Inc.
Via GlobeNewswire
BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates
From BioAge Labs, Inc.
Via GlobeNewswire
Notice to Long-Term Shareholders of BioAge Labs, Inc. (NASDAQ: BIOA); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Integra LifeSciences Holdings Corporation (NASDAQ: IART); and Monolithic Power Systems, Inc. (NASDAQ: MPWR): Grabar Law Office Investigates
From Grabar Law Office
Via GlobeNewswire
Notice to Long-Term Shareholders of BioAge Labs, Inc. (NASDAQ: BIOA); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Integra Lifesciences Holdings Corporation (NASDAQ: IART); and Monolithic Power Systems, Inc. (NASDAQ: MPWR): Grabar Law Office Investigates
From Grabar Law Office
Via GlobeNewswire
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of BioAge Labs, Inc. (NASDAQ: BIOA); NAPCO Security Technologies, Inc. (NASDAQ: NSSC); Treace Medical Concepts, Inc. (NASDAQ: TMCI); and Virtu Financial Inc. (NASDAQ: VIRT)
From Grabar Law Office
Via GlobeNewswire
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
From BioAge Labs, Inc.
Via GlobeNewswire
BIOA DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages BioAge Labs, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action – BIOA
From The Rosen Law Firm PA
Via GlobeNewswire
BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Final BIOA Deadline Reminder: March 10, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Via TheNewswire.com
Topics Initial Public Offering Lawsuit
Final BIOA Deadline Reminder: March 10, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Via NewMediaWire
Topics Initial Public Offering Lawsuit
BIOA Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds BioAge Labs, Inc. (BIOA) Investors of Filing Deadline in Class Action Lawsuit
Via NewMediaWire
Topics Initial Public Offering Lawsuit
BIOA Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds BioAge Labs, Inc. (BIOA) Investors of Filing Deadline in Class Action Lawsuit
Via TheNewswire.com
Topics Initial Public Offering Lawsuit
Deadline Soon: BioAge Labs, Inc. (BIOA) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire

Frequently Asked Questions

Is BioAge Labs, Inc. - Common Stock publicly traded?
Yes, BioAge Labs, Inc. - Common Stock is publicly traded.
What exchange does BioAge Labs, Inc. - Common Stock trade on?
BioAge Labs, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BioAge Labs, Inc. - Common Stock?
The ticker symbol for BioAge Labs, Inc. - Common Stock is BIOA on the Nasdaq Stock Market
What is the current price of BioAge Labs, Inc. - Common Stock?
The current price of BioAge Labs, Inc. - Common Stock is 6.010
When was BioAge Labs, Inc. - Common Stock last traded?
The last trade of BioAge Labs, Inc. - Common Stock was at 10/22/25 01:14 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.